arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Cytek Biosciences, Inc.

CTKB
$5.72 ▲ +0.43 (+8.13%) at close
Industrials ·Laboratory Analytical Instruments ·USLaboratory Analytical Instruments
27 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cytek Biosciences, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $740.5M
Dividend Yield
Revenue Growth 5.6%
Op. Margin -23.7%
ROIC -2.8%
FCF / Share $-0.01
Trailing P/E
Price / Book 2.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$48.14M
↑ +5.6%
Net Income Profit after all expenses
$-18.87M
↓ -65.5%
Operating Margin Operating profit as % of sales
-23.7%
↑ +43.4% 10th
FCF / Share Free cash flow per share
$-0.01
↑ +82.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
11
Returns
28
Cash Quality
27

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters